Affiliated Oncologists Announces Collaboration with Sarah Cannon Research Institute, Expanding Access to Cutting-Edge Cancer Trials in the Southwest Suburbs of Chicago

November 11, 2024

CHICAGO RIDGE, IL (November 11, 2024) – Affiliated Oncologists, through its affiliation with The US Oncology Network (The Network), announced a collaboration with Sarah Cannon Research Institute

(SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials.

Since its inception, SCRI has conducted more than 750 first-in-human trials and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. Our research program, SCRI at Affiliated Oncologists, will provide eligible patients with cancer the opportunity to enroll in the latest research trials.

“We are thrilled to partner with Sarah Cannon Research Institute on exciting new developments in clinical research,” said Angela Malone, Clinical Research Supervisor, Affiliated Oncologists. “This amazing opportunity affords us the ability to offer our patients the newest treatment options.”

The collaboration with SCRI offers numerous advantages for cancer patients:

• Greater Treatment Options: Eligible patients will have access to a wider range of clinical trials, offering options based on their individualized treatment plan.
• Access to Cutting-Edge Therapies: Eligible patients will have the opportunity to participate in trials evaluating the latest advancements in cancer research.
• Clinical trial matching technology: Affiliated Oncologists will have access to Genospace, highly specific trial matching based on patient clinical and genomic data, that works with SCRI’s Personalized Medicine team to identify potential clinical trial options based on a person’s individual cancer.

“By collaborating with the experts at Affiliated Oncologists, we can make a significant impact in the greater Chicago area for people living with cancer by expanding access to novel, cutting-edge treatment options,” said Dee Anna Smith, CEO of SCRI.

The relationship between Affiliated Oncologists and SCRI highlights Affiliated Oncologists’ dedication to providing the most advanced, personalized cancer care close to home.

About Affiliated Oncologists

For 50 years, we have been at the leading-edge of cancer care. When you are a patient at Affiliated Oncologists, you can expect innovative cancer care tailored to you using the latest treatments and technologies available, including clinical trials. Our cancer centers specialize in medical oncology, hematology, gynecologic oncology, radiation oncology and bone marrow transplants.

Affiliated Oncologists is rooted in the community and available in the South Chicago suburbs. We are available to provide care, resources and support for you and your family close to home.

Affiliated Oncologists is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 2,600 independent providers dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI joined with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.